logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Venetoclax+obinutuzumab extends PFS in frontline CLL

Unprecedented high and durable MRD negativity in elderly patients with comorbidities.